At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 220 enrolled
Drug / intervention
Losartan +1 moredrug
Likely dose
Losartan 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Losartan Effects on Emphysema Progression
In Brief
A Phase 4 clinical trial evaluating Losartan and Placebo for Emphysema. Completed, enrolled 220 participants across 28 sites.
Detailed Summary
A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan on the progression of emphysema as measured by quantitative HRCT compared to placebo .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEmphysema
CountriesUnited States
CollaboratorsUniversity of Pittsburgh
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMay 2017
Primary CompletionMar 2021
Study CompletionJun 2021
TodayJul 2026
First PostedMar 2, 2016
Enrollment StartMay 23, 2017
Primary CompletionMar 31, 2021
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.3 years ago
Interventions
Losartandrug
50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
Placebodrug
one capsule per day for two weeks, followed by two capsules per day for 46 weeks